Literature DB >> 20127241

Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection.

Susumu Eguchi1, Mitsuhisa Takatsuki, Masaaki Hidaka, Akihiko Soyama, Tetsuo Tomonaga, Izumi Muraoka, Takashi Kanematsu.   

Abstract

BACKGROUND: Microscopic vascular invasion is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. To predict microscopic portal venous invasion, the following two questions were examined retrospectively: Is it possible to detect microvascular invasion preoperatively? What are the characteristics of a group of early HCC recurrences even with no microvascular invasion?
METHODS: Study 1 included 229 patients with HCC who underwent curative liver resection between 1991 and 2008; 127 had HCC without microscopic portal venous invasion, and 52 had HCC with microscopic portal venous invasion (MPVI). These two distinct groups were analyzed with regard to various clinicopathologic factors. Subsequently, we specifically investigated if HCCs <5 cm with vascular invasion (n = 32) have some characteristics that would allow detection of latent microvascular invasion. Study 2 included 127 HCC patients without MVPI; 42 had a recurrence within 2 years, and 85 patients were recurrence-free for at least 2 years. These two distinct groups were analyzed with regard to various clinicopathologic factors.
RESULTS: HCC diameter of >5 cm, the macroscopic appearance of HCC, and high levels of preoperative des-gamma-carboxyprothrombin are significant prognostic factors in identifying microvascular invasion of HCC. The strongest predictor of early recurrence (within 2 years) was the serum alpha-fetoprotein level in patients without clear microvascular invasion.
CONCLUSIONS: Tumor size, macroscopic appearance, and high tumor marker levels are important elements in identifying the group of patients with a low HCC recurrence rate after curative liver resection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127241     DOI: 10.1007/s00268-010-0424-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  11 in total

1.  Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.

Authors:  Francis Y Yao; Linda Ferrell; Nathan M Bass; Peter Bacchetti; Nancy L Ascher; John P Roberts
Journal:  Liver Transpl       Date:  2002-09       Impact factor: 5.799

2.  The role of macroscopic classification in nodular-type hepatocellular carcinoma.

Authors:  M Shimada; T Rikimaru; T Hamatsu; Y Yamashita; T Terashi; K Taguchi; S Tanaka; K Shirabe; K Sugimachi
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

3.  Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters.

Authors:  Sasan Roayaie; Jason S Frischer; Sukru H Emre; Thomas M Fishbein; Patricia A Sheiner; Max Sung; Charles M Miller; Myron E Schwartz
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

4.  The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.

Authors:  Ken Shirabe; Shinji Itoh; Tomoharu Yoshizumi; Yuji Soejima; Akinobu Taketomi; Shin-Ichi Aishima; Yoshihiko Maehara
Journal:  J Surg Oncol       Date:  2007-03-01       Impact factor: 3.454

5.  Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma.

Authors:  Bong-Wan Kim; Young-Bae Kim; Hee-Jung Wang; Myung-Wook Kim
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

6.  Multicentric occurrence and spread of hepatocellular carcinoma in whole explanted end-stage liver.

Authors:  Masaaki Hidaka; Susumu Eguchi; Sadayuki Okudaira; Mitsuhisa Takatsuki; Hirotaka Tokai; Akihiko Soyama; Shigeki Nagayoshi; Satoshi Mochizuki; Koji Hamasaki; Yoshitsugu Tajima; Takashi Kanematsu
Journal:  Hepatol Res       Date:  2008-11-25       Impact factor: 4.288

7.  Hepatic resection versus transplantation for hepatocellular carcinoma.

Authors:  S Iwatsuki; T E Starzl; D G Sheahan; I Yokoyama; A J Demetris; S Todo; A G Tzakis; D H Van Thiel; B Carr; R Selby
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

8.  Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.

Authors:  Marco Vivarelli; Alessandro Cucchetti; Giuliano La Barba; Matteo Ravaioli; Massimo Del Gaudio; Augusto Lauro; Gian Luca Grazi; Antonio Daniele Pinna
Journal:  Ann Surg       Date:  2008-11       Impact factor: 12.969

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  56 in total

1.  Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies.

Authors:  Alfonso Reginelli; Angelo Vanzulli; Cristiano Sgrazzutti; Luca Caschera; Nicola Serra; Antonio Raucci; Fabrizio Urraro; Salvatore Cappabianca
Journal:  Med Oncol       Date:  2017-04-12       Impact factor: 3.064

2.  Microvascular infiltration has limited clinical value for treatment and prognosis in hepatocellular carcinoma.

Authors:  Nazario Portolani; Gian Luca Baiocchi; Sarah Molfino; Anna Benetti; Federico Gheza; Stefano Maria Giulini
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

3.  Proposal of objective morphological classification system for hepatocellular carcinoma using preoperative multiphase computed tomography.

Authors:  Hisashi Nakayama; Tadatoshi Takayama; Takao Okubo; Tokio Higaki; Yutaka Midorikawa; Masamichi Moriguchi; Akiyoshi Itoh
Journal:  J Gastroenterol       Date:  2013-11-16       Impact factor: 7.527

4.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

5.  Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas.

Authors:  Toshifumi Tada; Takashi Kumada; Hidenori Toyoda; Takanori Ito; Yasuhiro Sone; Yuji Kaneoka; Atsuyuki Maeda; Seiji Okuda; Katsuhiko Otobe; Kenichi Takahashi
Journal:  Eur Radiol       Date:  2014-06-22       Impact factor: 5.315

6.  Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography.

Authors:  Toshifumi Tada; Takashi Kumada; Hidenori Toyoda; Takanori Ito; Yasuhiro Sone; Seiji Okuda; Sadanobu Ogawa; Takumi Igura; Yasuharu Imai
Journal:  J Gastroenterol       Date:  2014-02-22       Impact factor: 7.527

Review 7.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

Review 8.  Liver transplantation for advanced hepatocellular carcinoma: how far can we go?

Authors:  Kyung-Suk Suh; Hae Won Lee
Journal:  Hepat Oncol       Date:  2015-01-12

9.  Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma.

Authors:  Jong Man Kim; Choon Hyuck; David Kwon; Jae-Won Joh; Joon Hyeok Lee; Seung Woon Paik; Cheol Keun Park
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

10.  Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma.

Authors:  Tae Wook Kang; Hyunchul Rhim; Jisun Lee; Kyoung Doo Song; Min Woo Lee; Young-Sun Kim; Hyo Keun Lim; Kyung Mi Jang; Seong Hyun Kim; Geum-Youn Gwak; Sin-Ho Jung
Journal:  Eur Radiol       Date:  2016-01-08       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.